Law360, New York (January 27, 2011, 2:39 PM ET) -- Human Genome Sciences Inc. has filed suit against Genentech Inc. and cancer center City of Hope, seeking a declaration that a patent assigned to the defendants is invalid and not infringed by lupus drug Benlysta.
HGS expects a decision from the U.S. Food and Drug Administration regarding the approval of its Biologic License Application for Benlysta in the near future, according to a complaint the company filed in the U.S. District Court for the District of Delaware on Tuesday.
Upon approval, HGS intends to start marketing...
HGS Sues Genentech To Protect Lupus Drug
To view the full article, take a free trial now.
